Acidosis: progression of chronic kidney disease and quality of life.

Abstract

Metabolic acidosis (MA) is relatively common in patients with chronic kidney disease (CKD) particularly in stages 4 and 5. It is assumed to play a contributory role in the development of several complications including bone disease, skeletal muscle wasting, altered protein synthesis, and degradation. Recent evidence also suggests that even mild acidosis might play a role in progressive glomerular filtration rate loss. Experimental and clinical studies suggest that correction of acidosis by alkali therapy attenuates these complications and improves quality of life. Despite several recent small and single-center studies supporting this notion, more robust evidence is required with regard to the long-term benefits of alkali therapy, type of alkali supplements, and the optimal level of serum bicarbonate.

• Authors: Ione de-Brito Ashurst, Emma O'Lone, Tarun Kaushik, Kieran McCafferty, Muhammad M Yaqoob
• Journal: Pediatric nephrology (Berlin, Germany) (Pediatr Nephrol) Vol. 30 Issue 6 Pg. 873-9 (Jun 2015) ISSN: 1432-198X [Electronic] Germany
• PMID: 25085611 (Publication Type: Journal Article, Review)

Chemical References

• Alkalies
• Sodium Bicarbonate

Topics

• Acidosis (blood, drug therapy, etiology, psychology)
• Age Factors
• Alkalies (adverse effects, therapeutic use)
• Animals
• Disease Progression
• Humans
• Hydrogen-Ion Concentration
• Quality of Life
• Renal Insufficiency, Chronic (blood, complications, drug therapy, psychology)
• Risk Factors
• Sodium Bicarbonate (adverse effects, blood, therapeutic use)
• Treatment Outcome